ATAI Life Sciences N.V. (ATAI): Price and Financial Metrics
GET POWR RATINGS... FREE!
ATAI POWR Grades
- ATAI scores best on the Growth dimension, with a Growth rank ahead of 85.16% of US stocks.
- ATAI's strongest trending metric is Momentum; it's been moving up over the last 179 days.
- ATAI ranks lowest in Quality; there it ranks in the 21st percentile.
ATAI Stock Summary
- ATAI's price/sales ratio is 1,177.56; that's higher than the P/S ratio of 99.62% of US stocks.
- With a year-over-year growth in debt of 1,690.1%, ATAI LIFE SCIENCES NV's debt growth rate surpasses 98.67% of about US stocks.
- Revenue growth over the past 12 months for ATAI LIFE SCIENCES NV comes in at -97.92%, a number that bests just 0.82% of the US stocks we're tracking.
- Stocks that are quantitatively similar to ATAI, based on their financial statements, market capitalization, and price volatility, are IONQ, QLGN, OLO, ROIV, and GWRE.
- Visit ATAI's SEC page to see the company's official filings. To visit the company's web site, go to www.atai.life.
ATAI Valuation Summary
- In comparison to the median Healthcare stock, ATAI's price/sales ratio is 25087.5% higher, now standing at 1209.
- Over the past 18 months, ATAI's price/sales ratio has gone NA NA.
Below are key valuation metrics over time for ATAI.
ATAI Stock Price Chart Interactive Chart >
ATAI Price/Volume Stats
|Current price||$3.16||52-week high||$11.92|
|Prev. close||$3.01||52-week low||$2.60|
|Day high||$3.30||Avg. volume||869,751|
|50-day MA||$3.09||Dividend yield||N/A|
|200-day MA||$4.09||Market Cap||524.17M|
ATAI Life Sciences N.V. (ATAI) Company Bio
Atai Life Sciences N.V. focuses on operating as a holding company for ATAI Life Sciences AG that operates as a clinical-stage biopharmaceutical company. It engages in developing various therapeutic candidates that are focused on multiple mental health disorders. The company's therapeutic candidates include PCN-101, a subcutaneous formulation of R-ketamine for the treatment of treatment-resistant depression (TRD); RL-007, a GABA/nicotinic modulator to treat cognitive impairment associated with schizophrenia; DMX-1002, an oral formulation of ibogaine for treating opioid use disorder (OUD); GRX-917, an oral formulation of a deuterated version of etifoxine for the generalized anxiety disorder treatment; and NN-101, a novel intranasal formulation of N-acetylcysteine to treat mild traumatic brain injuries. Its therapeutic candidates also comprise VLS-01 is a formulation of N,N-dimethyltryptamine for treating TRD; EMP-01, an oral formulation of an 3,4-methyl enedioxy methamphetamine for the treatment of post-traumatic stress disorder; RLS-01, a formulation of Salvinorin A for TRD; KUR-101, an oral formulation of deuterated mitragynine to treat OUD; and DMX-1001, an oral formulation of noribogaine for the treatment of OUD. The company was formerly known as Adripa Holding B.V. Atai Life Sciences N.V. was founded in 2018 and is headquartered in Berlin, Germany.
Most Popular Stories View All
ATAI Latest News Stream
|Loading, please wait...|
ATAI Latest Social Stream
View Full ATAI Social Stream
Latest ATAI News From Around the Web
Below are the latest news stories about ATAI LIFE SCIENCES NV that investors may wish to consider to help them evaluate ATAI as an investment opportunity.
There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on EDAP TMS (EDAP – Research Report) and ATAI Life Sciences (ATAI – Research Report) with bullish sentiments. EDAP TMS (EDAP) In a report released today, Swayampakula Ramakanth from H.C. Wainwright maintained a Buy rating on EDAP TMS, with a price target of $12.00. The company's shares closed last Thursday at $10.34, close to its 52-week high of $10.60. According to TipRanks.
Cathie Wood has built her career on holding contrarian views and her Ark Invest firm has been known to go against the grain. As such, 2022’s bear market has done little to change her stance. In fact, recently, Wood has been arguing that the Fed’s aggressive monetary stance in its ongoing efforts to curb soaring inflation is misguided. Highlighting deflationary signals, Wood says that unless it changes tack, the Fed’s actions could result in a repeat of the the Great Depression. “If the Fed does not pivot, the set-up will be more like 1929,” Wood opined.
atai Life Sciences and Massachusetts General Hospital Announce Initiation of Clinical Study Investigating Neuroplasticity Biomarkers in Treatment-Resistant Depression Patients Undergoing Ketamine Treatment
NEW YORK and BERLIN, Nov. 17, 2022 (GLOBE NEWSWIRE) -- atai Life Sciences N.V. (NASDAQ: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, today announced it has initiated a clinical study with Massachusetts General Hospital (MGH). The study will utilize a neuroimaging method to identify neuroplasticity biomarkers in patients with treatment-resistant depression (TRD) undergoing intravenous (IV) ketamine treatment. The main obj
In a report released yesterday, Jason McCarthy from Maxim Group maintained a Buy rating on ATAI Life Sciences (ATAI - Research Report), with a price target of $12.00. The company's shares opened today at $2.90.According to TipRanks, McCarthy is an analyst with an average return of -38.1% and a 14.47% success rate. McCarthy covers the Healthcare sector, focusing on stocks such as Immutep, Daré Bioscience, and Adial Pharmaceuticals.Currently, the analyst consensus on ATAI Life Sciences is a Strong Buy with an average price target of $25.25.
Last patient dosed in the Phase 2a proof-of-concept trial of PCN-101 (R-ketamine) for treatment-resistant depression (TRD), with topline results expected around year-end 2022.Announced positive preliminary pharmacokinetics and pharmacodynamics results in a Phase 1 study of GRX-917 (deuterated etifoxine) being developed for generalized anxiety disorder (GAD), demonstrating target engagement based on qEEG. Announced positive preliminary results of the single ascending dose (SAD) portion of the Pha
ATAI Price Returns